Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition.

Scott GK, Yau C, Becker BC, Khateeb S, Mahoney S, Jensen MB, Hann B, Cowen BJ, Pegan SD, Benz CC.

Mol Cancer Ther. 2019 Aug;18(8):1374-1385. doi: 10.1158/1535-7163.MCT-18-1323. Epub 2019 Jun 12.

PMID:
31189611
2.

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition.

Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC.

Oncotarget. 2016 Oct 18;8(48):83432-83445. doi: 10.18632/oncotarget.12735. eCollection 2017 Oct 13.

3.

Sources of superoxide/H2O2 during mitochondrial proline oxidation.

Goncalves RL, Rothschild DE, Quinlan CL, Scott GK, Benz CC, Brand MD.

Redox Biol. 2014 Jul 18;2:901-9. doi: 10.1016/j.redox.2014.07.003. eCollection 2014.

4.

RPL24: a potential therapeutic target whose depletion or acetylation inhibits polysome assembly and cancer cell growth.

Wilson-Edell KA, Kehasse A, Scott GK, Yau C, Rothschild DE, Schilling B, Gabriel BS, Yevtushenko MA, Hanson IM, Held JM, Gibson BW, Benz CC.

Oncotarget. 2014 Jul 15;5(13):5165-76.

5.

FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

Lal A, Chan L, Devries S, Chin K, Scott GK, Benz CC, Chen YY, Waldman FM, Hwang ES.

Breast Cancer Res Treat. 2013 Jun;139(2):381-90. doi: 10.1007/s10549-013-2556-4. Epub 2013 May 28.

PMID:
23712790
6.

Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.

Held JM, Britton DJ, Scott GK, Lee EL, Schilling B, Baldwin MA, Gibson BW, Benz CC.

Mol Cancer Res. 2012 Aug;10(8):1120-32. doi: 10.1158/1541-7786.MCR-12-0099. Epub 2012 Jun 5.

7.

MicroRNAs miR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8.

Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ, Campisi J.

Aging (Albany NY). 2009 Apr;1(4):402-11.

8.

Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network.

Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J.

Proc Natl Acad Sci U S A. 2009 Oct 6;106(40):17031-6. doi: 10.1073/pnas.0905299106. Epub 2009 Sep 28.

9.

Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.

Suzuki J, Chen YY, Scott GK, Devries S, Chin K, Benz CC, Waldman FM, Hwang ES.

Clin Cancer Res. 2009 May 1;15(9):3163-71. doi: 10.1158/1078-0432.CCR-08-2319. Epub 2009 Apr 21.

10.

Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis.

Hurst DR, Edmonds MD, Scott GK, Benz CC, Vaidya KS, Welch DR.

Cancer Res. 2009 Feb 15;69(4):1279-83. doi: 10.1158/0008-5472.CAN-08-3559. Epub 2009 Feb 3.

11.

Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites.

Atsriku C, Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW, Benz CC, Baldwin MA.

Mol Cell Proteomics. 2009 Mar;8(3):467-80. doi: 10.1074/mcp.M800282-MCP200. Epub 2008 Nov 3.

12.

Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.

Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schäfer S, Jung M, Benz CC.

Mol Cancer Res. 2008 Jul;6(7):1250-8. doi: 10.1158/1541-7786.MCR-07-2110.

13.

Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells.

Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC.

Oncogene. 2008 Sep 18;27(42):5643-7. doi: 10.1038/onc.2008.171. Epub 2008 May 26.

14.

A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells.

Britton DJ, Scott GK, Schilling B, Atsriku C, Held JM, Gibson BW, Benz CC, Baldwin MA.

J Am Soc Mass Spectrom. 2008 May;19(5):729-40. doi: 10.1016/j.jasms.2008.02.008. Epub 2008 Mar 4.

15.

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.

Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC.

Mol Pharmacol. 2007 Jun;71(6):1525-34. Epub 2007 Mar 28.

PMID:
17392524
16.

Quantification of cysteine oxidation in human estrogen receptor by mass spectrometry.

Atsriku C, Benz CC, Scott GK, Gibson BW, Baldwin MA.

Anal Chem. 2007 Apr 15;79(8):3083-90. Epub 2007 Mar 21.

17.

Novel pathways associated with quinone-induced stress in breast cancer cells.

Benz CC, Atsriku C, Yau C, Britton D, Schilling B, Gibson BW, Baldwin MA, Scott GK.

Drug Metab Rev. 2006;38(4):601-13. Review.

PMID:
17145690
18.

Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b.

Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC.

J Biol Chem. 2007 Jan 12;282(2):1479-86. Epub 2006 Nov 16.

19.

A PACS-1, GGA3 and CK2 complex regulates CI-MPR trafficking.

Scott GK, Fei H, Thomas L, Medigeshi GR, Thomas G.

EMBO J. 2006 Oct 4;25(19):4423-35. Epub 2006 Sep 14.

20.

Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers.

Benz CC, Fedele V, Xu F, Ylstra B, Ginzinger D, Yu M, Moore D, Hall RK, Wolff DJ, Disis ML, Eppenberger-Castori S, Eppenberger U, Schittulli F, Tommasi S, Paradiso A, Scott GK, Albertson DG.

Genes Chromosomes Cancer. 2006 Nov;45(11):983-94.

PMID:
16883574
21.

Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription.

Marx C, Berger C, Xu F, Amend C, Scott GK, Hann B, Park JW, Benz CC.

Assay Drug Dev Technol. 2006 Jun;4(3):273-84.

PMID:
16834533
22.

Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C.

Mol Cancer. 2006 Jun 19;5:24.

23.

Identification of a pH sensor in the furin propeptide that regulates enzyme activation.

Feliciangeli SF, Thomas L, Scott GK, Subbian E, Hung CH, Molloy SS, Jean F, Shinde U, Thomas G.

J Biol Chem. 2006 Jun 9;281(23):16108-16. Epub 2006 Apr 6.

24.

Rapid alteration of microRNA levels by histone deacetylase inhibition.

Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC.

Cancer Res. 2006 Feb 1;66(3):1277-81.

25.

Reactivity of zinc finger cysteines: chemical modifications within labile zinc fingers in estrogen receptor.

Atsriku C, Scott GK, Benz CC, Baldwin MA.

J Am Soc Mass Spectrom. 2005 Dec;16(12):2017-26. Epub 2005 Oct 24.

26.

Vitamin K3 (menadione)-induced oncosis associated with keratin 8 phosphorylation and histone H3 arylation.

Scott GK, Atsriku C, Kaminker P, Held J, Gibson B, Baldwin MA, Benz CC.

Mol Pharmacol. 2005 Sep;68(3):606-15. Epub 2005 Jun 6.

PMID:
15939799
27.

Clinical development of histone deacetylase inhibitors as anticancer agents.

Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC.

Annu Rev Pharmacol Toxicol. 2005;45:495-528. Review.

PMID:
15822187
28.

Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, Benz CC.

Int J Biochem Cell Biol. 2005 May;37(5):1130-44.

PMID:
15743683
29.

The phosphorylation state of an autoregulatory domain controls PACS-1-directed protein traffic.

Scott GK, Gu F, Crump CM, Thomas L, Wan L, Xiang Y, Thomas G.

EMBO J. 2003 Dec 1;22(23):6234-44.

30.
31.
32.

Age-dependent changes in breast cancer hormone receptors and oxidant stress markers.

Quong J, Eppenberger-Castori S, Moore D 3rd, Scott GK, Birrer MJ, Kueng W, Eppenberger U, Benz CC.

Breast Cancer Res Treat. 2002 Dec;76(3):221-36.

PMID:
12462383
33.

Ets regulation of the erbB2 promoter.

Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ 3rd, Thor AD, Benz CC.

Oncogene. 2000 Dec 18;19(55):6490-502.

34.

Targeting of PKA to glutamate receptors through a MAGUK-AKAP complex.

Colledge M, Dean RA, Scott GK, Langeberg LK, Huganir RL, Scott JD.

Neuron. 2000 Jul;27(1):107-19.

35.

Targeting the ets binding site of the HER2/neu promoter with pyrrole-imidazole polyamides.

Chiang SY, Burli RW, Benz CC, Gawron L, Scott GK, Dervan PB, Beerman TA.

J Biol Chem. 2000 Aug 11;275(32):24246-54.

36.

Alternative splicing regulates the subcellular localization of A-kinase anchoring protein 18 isoforms.

Trotter KW, Fraser ID, Scott GK, Stutts MJ, Scott JD, Milgram SL.

J Cell Biol. 1999 Dec 27;147(7):1481-92.

37.

The synthesis and antibacterial activity of totarol derivatives. Part 1: modifications of ring-C and pro-drugs.

Evans GB, Furneaux RH, Gravestock MB, Lynch GP, Scott GK.

Bioorg Med Chem. 1999 Sep;7(9):1953-64.

PMID:
10530944
39.

Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC.

Clin Cancer Res. 1999 Feb;5(2):251-6.

40.

Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer.

Liang X, Lu B, Scott GK, Chang CH, Baldwin MA, Benz CC.

Mol Cell Endocrinol. 1998 Nov 25;146(1-2):151-61.

PMID:
10022773
41.

The epithelium-specific ets transcription factor ESX is associated with mammary gland development and involution.

Neve R, Chang CH, Scott GK, Wong A, Friis RR, Hynes NE, Benz CC.

FASEB J. 1998 Nov;12(14):1541-50.

PMID:
9806763
42.

Polyamine inhibition of estrogen receptor (ER) DNA-binding and ligand-binding functions.

Lu B, Liang X, Scott GK, Chang CH, Baldwin MA, Thomas T, Benz CC.

Breast Cancer Res Treat. 1998 Apr;48(3):243-57.

PMID:
9598871
43.

HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer.

Benz CC, O'Hagan RC, Richter B, Scott GK, Chang CH, Xiong X, Chew K, Ljung BM, Edgerton S, Thor A, Hassell JA.

Oncogene. 1997 Sep 25;15(13):1513-25.

44.

Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.

Johnston SR, Lu B, Dowsett M, Liang X, Kaufmann M, Scott GK, Osborne CK, Benz CC.

Cancer Res. 1997 Sep 1;57(17):3723-7.

45.

ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis.

Chang CH, Scott GK, Kuo WL, Xiong X, Suzdaltseva Y, Park JW, Sayre P, Erny K, Collins C, Gray JW, Benz CC.

Oncogene. 1997 Apr 3;14(13):1617-22.

46.

Check bite impressions using irreversible alginate/reversible hydrocolloid combination.

Scott GK, Hawkins L, Chetwyn J, Doughty T.

J Prosthet Dent. 1997 Jan;77(1):83-5.

PMID:
9029470
47.

Further evidence for the mitogenic action of urinary trypsin inhibitor.

Manilal SB, Scott GK.

Biochem Mol Biol Int. 1996 Jul;39(4):711-20.

PMID:
8843339
48.

Biphasic modulation of cell growth by recombinant human galectin-1.

Adams L, Scott GK, Weinberg CS.

Biochim Biophys Acta. 1996 Jun 13;1312(2):137-44.

49.

Evidence of post-transcriptional regulation of U6 small nuclear RNA.

Noonberg SB, Scott GK, Benz CC.

J Biol Chem. 1996 May 3;271(18):10477-81.

50.

Supplemental Content

Loading ...
Support Center